Pure Global
NCT05811793

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

Efficacy and Safety of Superselective Cerebral Arterial Infusion of Bevacizumab Combined With Intrathecal Injection of Tislelizumab in the Treatment of Recurrent Glioblastoma
Second Affiliated Hospital of Nanchang University·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Glioblastoma
Drug/Device/Intervention
Tislelizumab and Bevacizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Second Affiliated Hospital of Nanchang University
Timeline & enrollment
Phase
N/A
Start date
Apr 15, 2023
End date
Dec 30, 2025
Enrollment
36 participants
Primary outcome

Progression-Free Survival

Summary

To investigate the efficacy, safety and tolerability of superselective cerebral arterial
 infusion of Bevacizumab combined with intrathecal injection of Tislelizumab in the treatment
 of recurrent glioblastoma

ICD-10 classifications
Malignant neoplasm of brainMalignant neoplasm: Brain, unspecifiedMesotheliomaMalignant neoplasm: Brain stemMalignant neoplasm: Overlapping lesion of brain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05811793
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05811793 through Pure Global AI's free database. This phase not specified trial is sponsored by Second Affiliated Hospital of Nanchang University and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.